EP0039771B1 - Cyclopropanderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung - Google Patents

Cyclopropanderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung Download PDF

Info

Publication number
EP0039771B1
EP0039771B1 EP81102377A EP81102377A EP0039771B1 EP 0039771 B1 EP0039771 B1 EP 0039771B1 EP 81102377 A EP81102377 A EP 81102377A EP 81102377 A EP81102377 A EP 81102377A EP 0039771 B1 EP0039771 B1 EP 0039771B1
Authority
EP
European Patent Office
Prior art keywords
cyclopropyl
methylamino
benzyl
propan
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP81102377A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0039771A1 (de
Inventor
Hans-Heinrich Dr. Hausberg
Jürgen Dr. Uhl
Christoph Dr. Seyfried
Klaus-Otto Dr. Minck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to AT81102377T priority Critical patent/ATE5068T1/de
Publication of EP0039771A1 publication Critical patent/EP0039771A1/de
Application granted granted Critical
Publication of EP0039771B1 publication Critical patent/EP0039771B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the object of the invention was to find new compounds which can be used for the production of medicaments. This object was achieved by providing the compounds of the formula 1.
  • the compounds of the formula and their physiologically acceptable acid addition salts have valuable pharmacological properties. In particular, they show effects on the central nervous system, especially antidepressant effects.
  • a reserpine antagonistic effect (detectable, for example, in mice compared to reserpine based on the method of Askew, Life Science, Vol. 10 [1963], pages 725-730), an anticataleptic effect (detectable, for example, on Rats compared to tetrabenazine based on the method of Giurgea et al., Medicina Experimentalis, Vol.
  • the invention relates to the cyclopropane derivatives of the formula I and their physiologically acceptable acid addition salts.
  • alkyl is preferably methyl, and also ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
  • Alkoxy (in the remainder Ar) is preferably methoxy, further also ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
  • Alkenyloxy (in the remainder Ar) is preferably allyloxy, further also vinyloxy, propenyloxy, isopropenyloxy, 1-buten-1- or -2-yloxy, 2-buten-1- or -2-yloxy, 3-buten-1- or - 2-yloxy, 2-methyl-1-propen-1- or -2-yloxy or 2-methyl-2-propen-1-yloxy.
  • Alkylthio (in the rest Ar) is preferably methylthio, further also ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio or tert-butylthio.
  • the radical Ar is preferably a monosubstituted phenyl group, but it can also in particular represent an unsubstituted or a doubly substituted phenyl group, furthermore also a triple, tetrasubstituted or pentasubstituted phenyl group.
  • the radical Ar preferably denotes fluorophenyl, chlorophenyl, methoxyphenyl, allyloxyphenyl, methylthiophenyl, hydroxyphenyl, mercaptophenyl, cyanophenyl or in particular trifluoromethylphenyl, in particular in particular m- or p-fluorophenyl, p-chlorophenyl, o-, m- or p-methoxyphenyl, o-allyloxyphenyl, p-methylthiophenyl or p-trifluoromethylphenyl.
  • Farther Ar preferably represents o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-fluorophenyl, o- or m-chlorophenyl, o-, m- or p-bromophenyl, o-, m- or p-ethoxyphenyl, o-, m- or pn-propoxyphenyl, o-, m- or p-isopropoxyphenyl, o-, m- or p-vinyloxyphenyl, m- or p-allyloxyphenyl, o- or m-methylthiophenyl, o -, m- or ethylthiophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-mercaptophenyl, o-, m- or p-cyanopheny
  • disubstituted phenyl groups is dimethoxyphenyl, in particular 3,4-dimethoxyphenyl, among the triply substituted trimethoxyphenyl, in particular 3,4,5-trimethoxyphenyl.
  • the radical R is preferably H, further preferably methyl or benzyl, furthermore in particular ethyl.
  • the compounds of formula I can have one or more asymmetric carbon atoms. They can therefore be present as racemates, if several asymmetric carbon atoms are present, as mixtures of several racemates and in various optically active forms.
  • the compounds of the formula I are otherwise prepared by methods known per se, as described in the literature (for example in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg Thieme-Verlag, Stuttgart; Organic Reactions, John Wiley & Sons, Inc., New York) are described, under reaction conditions as are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in detail.
  • the starting materials of the formulas II and III can also be formed in situ in such a way that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula.
  • the compounds of formula 1 are preferably obtained by reacting the phenols of formula II or - preferably - their salts with the amines of formula III.
  • the phenols of formula II are largely known and can be prepared by methods known per se, for. B. by cleavage of appropriate benzyl or methyl ether.
  • the radical X preferably denotes CI or Br.
  • inorganic halides such as SOCl 2 , PBr 3 or HJ
  • the phenol II is advantageously first converted into a salt, in particular into a metal salt, for. B. an alkali metal salt (Li, Na or K salt) or thalium salt.
  • a metal salt-forming reagent e.g. An alkali metal (e.g. Na), an alkali metal hydride or amide (e.g. LiH, NaH, NaNH 2 or KNH 2 ), a metal alcoholate (in which the alcohol part preferably has 1 -4 C atoms, e.g. lithium, sodium, potassium or thallium methylate, ethylate or tert-butoxide), an organometallic compound (e.g.
  • a metal salt-forming reagent e.g. An alkali metal (e.g. Na), an alkali metal hydride or amide (e.g. LiH, NaH, NaNH 2 or KNH 2 ), a metal alcoholate (in which the alcohol part preferably has 1 -4 C atoms,
  • Suitable solvents are e.g. B. hydrocarbons (such as hexane, benzene, toluene or xylene), ether (such as diethyl ether, diisopropyl ether, tetrahydrofuran [THF], dioxane or diethylene glycol dimethyl ether), amides such as dimethylformamide (DMF), alcohols (such as methanol or ethanol).
  • the phenol II or its salt is reacted with the amine III preferably in the presence of a diluent, e.g. B. of the solvent which has been used for the production of the salt, but which can be replaced by another solvent or diluted with such.
  • a diluent e.g. B. of the solvent which has been used for the production of the salt, but which can be replaced by another solvent or diluted with such.
  • the reaction is usually carried out at temperatures between about -20 and 150 °, preferably between 20 and 120 °.
  • the phenolate can also be formed in situ.
  • the phenol II and the amine III are allowed to react with each other in the presence of a base.
  • a dehydrating agent e.g. B. an azodicarboxylic acid dialkyl ester in the presence of triphenylphosphine in an inert solvent such as THF at about -10 to + 30 °.
  • cyclopropane derivatives of the formula can also be obtained by reacting compounds of the formula IV with amines of the formula V.
  • organometallic compounds of the formula M-CH 2 CH (Oalkyl) 2 in which M is Li, MgCl or MgBr
  • the compounds of the formulas IV and V are reacted under alkylation conditions, advantageously in the presence of one of the inert solvents mentioned, at temperatures between about 20 and 140 °, preferably 80 and 120 °. If volatile starting materials of the formula V are used, it can be advantageous to work under pressure (up to about 100 at).
  • cyclopropane derivatives of the formula I can also be prepared from amines of the formula VI by alkylation, in particular methylation.
  • the amines of the formula VI can, for. B. from the compounds of formula IV and ammonia.
  • Alkylation of the amines of the formula VI is advantageously carried out under the same conditions as the reaction of IV with V.
  • the amines of the formula VI can be condensed with aldehydes or ketones to form aldehyde-ammonia compounds, Schiff bases or enamines and then either hydrogenated or treated with an alkylating agent and the resulting quaternary salt then hydrolyzed.
  • alkylate with aldehydes or ketones under reducing conditions, the corresponding aldehyde ammonia being formed as intermediates.
  • one or two methyl groups can be introduced with formaldehyde in the presence of formic acid.
  • a compound which corresponds to the formula I but instead of a hydrogen atom it also contains a solvolytically cleavable group (preferably an N-acyl, 0-acyl, S-acyl or N-cyano group) by this group Treat with a solvolysing agent.
  • a solvolytically cleavable group preferably an N-acyl, 0-acyl, S-acyl or N-cyano group
  • the starting materials of formula VII are e.g. B. obtainable by reacting compounds of the formula IV with compounds of the formula HNR 1 -CH 3 or by reacting compounds of the formula cyclopropyl-CHX-CH 2 -CH 2 -NR 1 -CH 3 with phenols of the formula Ar-OH (II ).
  • starting materials are suitable which correspond to the formula, but carry an acyloxy or acylthio group in the Ar radical instead of an OH or SH group, each having 1-7 C atoms in the acyl radical.
  • the solvolysis of these compounds is advantageously carried out by the action of a solvent such as water (hydrolysis) or an alcohol with preferably 1 -4 C atoms (alcoholysis) in the presence of an acidic or basic catalyst, for.
  • a solvent such as water (hydrolysis) or an alcohol with preferably 1 -4 C atoms (alcoholysis) in the presence of an acidic or basic catalyst, for.
  • B a mineral acid such as sulfuric acid or hydrochloric acid, a metal hydroxide such as sodium, potassium, calcium, barium, lead or silver hydroxide, or a metal or ammonium salt such as sodium or potassium carbonate or ammonium chloride.
  • Methanol, ethanol or isopropanol are preferably used as alcohols, and mixtures of water with one of these alcohols can also be used.
  • the solvolysis is expediently carried out at temperatures between about 0 and about 120 °.
  • the cyclopropane derivatives of the formula I can furthermore be prepared by reducing corresponding starting materials which additionally contain reducible groups and / or C-C and / or C - N double or triple bonds.
  • the compounds of the formula VIII can be obtained, for example, by reacting phenols of the formula Ar-OH (II) with cyclopropane derivatives of the formula cyclopropyl-CHX-Q (in which Ar, X and Q have the meanings given).
  • Amides of the formula VIII, in which Q is -CH 2 -CO-NR-CH 3 also by amidation of corresponding 3-cyclopropyl-3-aryloxypropane acids or their esters.
  • the starting materials of the formula VIII and the other reducible starting materials can be converted into the compounds of the formula, for example, by catalytic hydrogenation, with nascent hydrogen, with complex metal hydrides or with the aid of other chemical reducing agents.
  • the reduction methods suitable for the individual starting materials generally depend on the type of group and are familiar to the person skilled in the art according to the information in the literature. So z. B. Schiff bases and olefinic compounds are particularly advantageously catalytically hydrogenated. In contrast, the reduction of the acid amides is particularly advantageous with complex metal hydrides or with diborane.
  • Precious metal, nickel or cobalt catalysts, for example, and mixed catalysts such as copper chromium oxide are also suitable for catalytic hydrogenations.
  • Platinum and palladium which can be present on supports (e.g. on carbon, calcium carbonate or strontium carbonate), as oxides (e.g. platinum oxide) or in finely divided form, are primarily considered as noble metals.
  • Nickel and cobalt catalysts are expediently used as Raney metals. You can expediently hydrogenate at pressures between about 1 and 200 at and at temperatures between about -80 and + 150 °. The hydrogenation takes place in the presence of an inert solvent, e.g. B.
  • an alcohol such as methanol, ethanol or isopropanol
  • a carboxylic acid such as acetic acid
  • an ester such as ethyl acetate
  • an ether such as tetrahydrofuran (THF) or dioxane.
  • solvent mixtures e.g. B. also mixtures containing water. Hydrogenation under mild conditions, e.g. B. at temperatures between 0 and 30 ° under normal pressure.
  • Complex metal hydrides such as LiAIH 4 , NaBH 4 or NaAI (OCH2CH2OCH3) 2H2 and diborane can also be used as reducing agents, if desired, with the addition of catalysts such as BF 3 , AlCl 3 or LiBr.
  • Suitable solvents for this are in particular ethers such as diethyl ether, THF, dioxane, 1,2-dimethoxyethane or diglyme, and hydrocarbons such as benzene.
  • alcohols such as methanol or ethanol are primarily suitable as solvents. According to this method, it is preferably reduced at temperatures between about -80 and + 150 °, in particular between about 20 and 120 °.
  • the reaction with nascent hydrogen is also suitable as a reduction method. This can be generated, for example, by treating metals with acids or bases.
  • the systems zinc / acid, zinc / alkali, iron / acid or tin / acid can be used.
  • acids are such.
  • An alkali metal detail such as sodium in an alcohol such as ethanol, isopropanol, n-butanol, amyl alcohol, isoamyl alcohol or in phenol can also be used as a reducing agent.
  • reaction temperatures are between about 0 and about 150 °, preferably between about 20 and 120 °.
  • Suitable N-alkylating agents are, for. B. the corresponding alkyl halides, for.
  • methyl chloride methyl bromide, methyl iodide, ethyl chloride, ethyl bromide, ethyl iodide, n-propyl chloride, bromide or iodide, etc., furthermore the corresponding dialkyl sulfates such as dimethyl sulfate and the corresponding alkyl sulfonates such as p-toluenesulfonic acid methyl ester.
  • a methyl group can also be introduced, for example, by treatment with formic acid and aqueous formaldehyde solution, expediently by heating to temperatures between 50 and 100 ° for several hours.
  • the N-alkylation is expediently carried out in the presence or absence of an inert solvent at temperatures between about 0 and about 120 °, preferably between 40 and 100 °, although a catalyst may also be present, preferably a base such as potassium tert. butylate.
  • a hydrogenation catalyst e.g. Raney nickel
  • Alkylation is also possible in several stages.
  • Reduce tertiary amine for example with a complex metal hydride such as LiAIH 4 in an inert solvent such as diethyl ether or THF, preferably at temperatures between 20 and 60 °.
  • benzylating agents for example benzyl halides such as benzyl chloride or bromide
  • Suitable alkylating agents are, for. B. the above-mentioned alkyl halides, dialkyl sulfates and sulfonic acid alkyl esters, as the alkenylating agent, the corresponding alkenyl halides (e.g. Allyl chloride, bromide or iodide).
  • the O-alkylation (or alkenylation) is advantageously carried out at temperatures between about 0 and about 150 °, preferably between 20 and 100 °, in an inert solvent, for.
  • an alcohol such as methanol or ethanol, a hydrocarbon such as benzene, an amide such as DMF, an ether such as THF or an amine such as pyridine.
  • a base such as NaOH, KOH, triethylamine or pyridine, an excess of this base being able to serve as a solvent.
  • the benzyl group can be removed by methods known per se, e.g. B. by hydrogenolysis in the presence of a noble metal catalyst or stepwise using a dealkylating agent, e.g. B. by reaction with chloramic acid, ethyl, phenyl, trichloromethyl or -2,2,2-trichloroethyl ester in the presence of a base to the corresponding urethane, which is then reductively, for. B. with zinc / acetic acid, or hydrolytically, e.g. B. is split with a base.
  • a dealkylating agent e.g. B. by reaction with chloramic acid, ethyl, phenyl, trichloromethyl or -2,2,2-trichloroethyl ester in the presence of a base to the corresponding urethane, which is then reductively, for. B. with zinc / acetic acid, or hydrolytically, e.g
  • the ether columns can be treated by treatment with HBr or HJ in aqueous or acetic acid solution, by heating with Lewis acids such as AlCl 3 or boron trihalides or by melting with pyridine or aniline hydrohalides, preferably pyridine hydrochloride, at about 150-250 °.
  • a base of the formula I obtained can be converted into the associated acid addition salt using an acid.
  • Acids which provide physiologically acceptable salts are suitable for this reaction.
  • So inorganic acids can be used, e.g. B. sulfuric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, nitric acid, sulfamic acid, also organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, such as formic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, acetic acid, Propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid,
  • the invention further relates to the use of the compounds of the formula I and their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route.
  • they can be brought into a suitable dosage form together with at least one carrier or auxiliary and, if appropriate, in combination with one or more further active ingredient (s).
  • the invention further relates to agents, in particular pharmaceutical preparations, containing a compound of formula 1 and / or one of its physiologically acceptable acid addition salts.
  • agents in particular pharmaceutical preparations, containing a compound of formula 1 and / or one of its physiologically acceptable acid addition salts.
  • These preparations can be used as pharmaceuticals in human or veterinary medicine.
  • Suitable carrier substances are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as Lactose or starch, magnesium stearate, talc, petroleum jelly.
  • Tablets, coated tablets, capsules, syrups, juices, drops or suppositories are used in particular for enteral application, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for parenteral application, and ointments, creams or powder for topical application.
  • the new compounds can also be lyophilized and the lyophilizates obtained, for. B. can be used for the preparation of injectables.
  • the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colors, flavors and / or flavorings. If desired, they can also contain one or more other active ingredients, e.g. B. one or more vitamins.
  • the invention further relates to the use of the compounds of the formula I and their physiologically acceptable acid addition salts for combating diseases, in particular depressions of various ethiology and symptomatology, and their use in the therapeutic treatment of the human or animal body.
  • the substances according to the invention are generally administered in analogy to known, commercially available psychopharmaceuticals (for example imipramine), preferably in doses between about 2 and 500 mg, in particular between 10 and 50 mg per dosage unit.
  • the daily dosage is preferably between about 0.05 and 10 mg / kg body weight.
  • the specific dose for each particular patient depends on a variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination, combination of drugs and The severity of the disease to which the therapy applies. Oral application is preferred.
  • Example 112 Analogously to Example 112, reaction of the corresponding 1-p-toluenesulfonyloxy, 1-chloro or 1-bromo-3-cyclopropyl-3-aryloxypropane with methylamine, dimethylamine, N-benzyl-N-methylamine, N-ethyl is obtained -N-methylamine or Nn-butyl-N-methylamine the compounds given in Examples 5 to 111.
  • the less volatile amines can also be used without pressure and / or higher-boiling solvents such as isopropanol or n-butanol can be used.
  • Example 220 Analogously to Example 220, the compounds given in Examples 5 to 111 are obtained by adding the abovementioned amines to the corresponding 3-cyclopropyl-3-aryloxypropene.
  • a solution of 2.59 g of 1-amino-3-cyclopropyl-3-p-trifluoromethylphenoxypropane (obtainable by condensation of ethyl cyclopropanecarboxylate with ethyl acetate to 3-cyclopropyl-propan-3-one-1-acidic acid ethyl ester, reduction to 3-cyclopropyl -propan-3-ol-l-acidic acid ethyl ester, reaction with p-trifluoromethylphenol analogously to Example 3 to 3-cyclopropyl-3-p-trifluoromethylphenoxy propanoic acid ethyl ester, reaction with NH 3 to the amide and reduction with LiAlH 4 ) and 1.5 g of benzaldehyde in 25 ml of toluene is boiled for one hour on a water separator.
  • Example 328 Analogously to Example 328, the compounds given in Examples 5 to 41 are obtained by methylating the corresponding 1-amino-3-cyclopropyl-3-aryloxypropane.
  • a mixture of 29.6 g of 1-amino-3-cyclopropyl-3-trifluoromethylphenoxypropane hydrochloride, 50 ml of formic acid, 7 g of sodium formate and 40 ml of 40% formaldehyde solution is heated to 60 ° for 3 hours and then for 12 hours 100 ° heated. After the usual work-up, 1-dimethylamino-3-cyclopropyl-3-p-trifluoromethylphenoxypropane is obtained.
  • Example 366 Analogously to Example 366, the compounds described in Examples 42 to 75 are obtained from the corresponding 1-amino-3-cyclopropyl-3-aryloxypropanes with formic acid / sodium formate / formaldehyde.
  • a mixture of 29.8 g of 1-N-methyl-N-cyanoamino-3-cyclopropyl-3-trifluoromethylphenoxypropane (obtainable by reaction of 1-dimethylamino-3-cyclopropyl-3-p-trifluoromethylphenoxypropane with BrCN), 300 g KOH, 250 ml water and 1200 ml ethylene glycol is boiled for 20 hours, cooled and worked up as usual.
  • 1-Methylamino-3-cyclopropyl-3-p-trifluoromethylphenoxypropane is obtained. Rf 0.22 (A).
  • Example 401 Analogously to Example 401, the compounds given in Examples 5 to 41 are obtained by reacting the corresponding 1-N-methyl-N-cyano-amino-3-cyclopropyl-3-aryloxypropane with KOH.
  • Example 439 the compounds given in Examples 5 to 41 are obtained from corresponding 1-N-methyl-N-acylamino-3-cyclopropyl-3-aryloxypropanes by alkaline hydrolysis.
  • a solution of 28.7 g of 3-cyclopropyl-3-p-trifluoromethylphenoxypropanoic acid-N-methylamide (obtainable by reacting the corresponding ethyl ester) is added dropwise to a suspension of 7.6 g of LiA) H 4 in 250 ml of absolute THF with stirring with methylamine) in 500 ml THF, boiled for 16 hours, mixed with cooling with ethyl acetate, then with 32% sodium hydroxide solution, worked up as usual and received 1-methylamino-3-cyclopropyl-3-p-trifluoromethyl-phenoxy-propane. Rf 0.22 (A).
  • 1-dimethylamino-3-cyclopropyl-3-p-mercaptophenoxy-propane is obtained from 1-dimethylamino-3-cyclopropyl-3-p-methylthiophenoxypropane with pyridine hydrochloride.
  • 1-dimethylamino-3-cyclopropyl-3-p-methylthiophenoxy-propane is obtained from 1-dimethylamino-3-cyclopropyl-3-p-mercaptophenoxypropane with dimethyl sulfate.
  • a mixture of 1 kg of 1-methylamino-3-cyclopropyl-3-p-trifluoromethyl-phenoxypropane hydrochloride, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is used in a conventional manner pressed into tablets such that each tablet contains 10 mg of active ingredient.
  • Example A Analogously to Example A, tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
  • a solution of 1 kg of 1-methylamino-3-cyclopropyl-3-p-trifluoromethyl-phenoxypropane hydrochloride in 301 double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.
  • tablets, dragees, capsules and ampoules which contain one or more of the other active compounds of the formula I and / or their physiologically acceptable acid addition salts.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
EP81102377A 1980-05-09 1981-03-30 Cyclopropanderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung Expired EP0039771B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT81102377T ATE5068T1 (de) 1980-05-09 1981-03-30 Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3017812 1980-05-09
DE19803017812 DE3017812A1 (de) 1980-05-09 1980-05-09 Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
EP0039771A1 EP0039771A1 (de) 1981-11-18
EP0039771B1 true EP0039771B1 (de) 1983-10-19

Family

ID=6102013

Family Applications (1)

Application Number Title Priority Date Filing Date
EP81102377A Expired EP0039771B1 (de) 1980-05-09 1981-03-30 Cyclopropanderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung

Country Status (11)

Country Link
US (1) US4500541A (es)
EP (1) EP0039771B1 (es)
JP (1) JPS574950A (es)
AT (1) ATE5068T1 (es)
AU (1) AU540658B2 (es)
CA (1) CA1178597A (es)
DE (2) DE3017812A1 (es)
ES (1) ES502029A0 (es)
HU (1) HU186768B (es)
IL (1) IL62815A (es)
ZA (1) ZA813093B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6030038U (ja) * 1983-08-08 1985-02-28 アルプス電気株式会社 入力装置
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
DK630987D0 (da) * 1987-12-01 1987-12-01 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
US5238959A (en) * 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
US6051539A (en) * 1998-07-02 2000-04-18 Cargill, Inc. Process for modifying unsaturated triacylglycerol oils resulting products and uses thereof
US6291409B1 (en) * 1998-07-02 2001-09-18 Cargill, Inc. Process for modifying unsaturated triacylglycerol oils; Resulting products and uses thereof
US6992037B2 (en) * 2001-09-17 2006-01-31 Engelhard Corporation Precious metal catalyst for debenzylation
US7659225B2 (en) * 2001-09-17 2010-02-09 Basf Catalysts Llc Precious metal catalyst for debenzylation
WO2006021565A1 (en) * 2004-08-26 2006-03-02 Neurosearch A/S Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors
JP2008510775A (ja) * 2004-08-26 2008-04-10 ノイロサーチ アクティーゼルスカブ モノアミン神経伝達物質再取込み阻害剤としての新規な置換アリールオキシアルキルアミン及びそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT196386B (de) * 1954-04-08 1958-03-10 Pharmazeutische Fabrik Montavit Gmbh Verfahren zur Herstellung von am Stickstoff symmetrisch oder unsymmetrisch disubstituierten Aminoalkyläthern aromatisch-aliphatischer Alkohole und deren Salzen
GB951461A (en) * 1959-11-17 1964-03-04 Smith Kline French Lab Improvements in or relating to substituted 2-phenoxy-cyclopropylamines
US3253040A (en) * 1962-12-10 1966-05-24 Union Carbide Corp Process for the production of primary 3-hydrocarbyloxypropylamines
CH485645A (de) * 1963-11-05 1970-02-15 Whitefin Holding Sa Verfahren zur Herstellung von neuen Phenylzyklopropanverbindungen
US3928426A (en) * 1972-01-28 1975-12-23 Robins Co Inc A H 1-Cyclopropyl-1-phenyl-omega-amino-1-lower alkanoyloxyalkanes
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines

Also Published As

Publication number Publication date
ES8301887A1 (es) 1983-01-01
IL62815A0 (en) 1981-07-31
IL62815A (en) 1984-08-31
CA1178597A (en) 1984-11-27
HU186768B (en) 1985-09-30
ATE5068T1 (de) 1983-11-15
EP0039771A1 (de) 1981-11-18
US4500541A (en) 1985-02-19
DE3161219D1 (en) 1983-11-24
DE3017812A1 (de) 1981-11-12
ES502029A0 (es) 1983-01-01
AU6918481A (en) 1981-11-12
ZA813093B (en) 1982-05-26
JPS574950A (en) 1982-01-11
AU540658B2 (en) 1984-11-29

Similar Documents

Publication Publication Date Title
EP0005848B1 (de) N-Alkylierte Aminoalkohole und ihre Salze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE2901032C2 (de) Substituierte Morpholin-Derivate und deren Verwendung
US4148923A (en) 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
DE2645710A1 (de) Phenoxy-amino-propanole und verfahren zu ihrer herstellung
EP0039771B1 (de) Cyclopropanderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
CS266593B2 (en) Method of 2-(2-hydroxy-3-phenosypropylamine) ethoxyphenolh's derivativesprodduction
DE1643262A1 (de) Neue 1-Phenoxy-2-hydroxy-3-alkylaminopropane und Verfahren zu ihrer Herstellung
DE69019293T2 (de) Naphthyloxazolidon-Derivate.
EP0004532A1 (de) 1-Aryloxy-3-nitratoalkylamino-2-propanole, Verfahren zu ihrer Herstellung und ihre pharmazeutischen Zubereitungen
EP0031885B1 (de) Basische Äther, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
DE3411993A1 (de) Substituierte benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimittel
DE3026534A1 (de) 3,1-benzoxazin-2-one, ihre herstellung und verwendung
EP0586866A2 (de) 1,4-Benzodioxanderivate mit pharmakologischen Eigenschaften
EP0004288A2 (de) Phenoxyalkylamine, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
DE1943150A1 (de) Chemische Verfahren
EP0031910B1 (de) Anilinderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
CH636076A5 (de) Benzylalkoholderivate und verfahren zu deren herstellung.
EP0175249A2 (de) Neue Phenyl-acetonitril-Derivate
DE2048838A1 (de) Neue 1 Phenoxy 2 hydroxy 3 hydroxyal kylaminopropane und Verfahren zu ihrer Her stellung
EP0980351B1 (de) Benzylaminderivate und phenylethylaminderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DD157796A5 (de) Verfahren zur herstellung neuer derivate des 2-amino-aethanols
DE2106620C3 (de) ureidobenzylalkohole und Verfahren zu ihrer Herstellung
DE2421165A1 (de) N-substituierte dihydroxyphenylaethylamine
DE2324584A1 (de) Neue amine und verfahren zu ihrer herstellung
DD210266A5 (de) Verfahren zur herstellung von 3-(ureidocyclohexylamino)-propan-1,2-diolderivaten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT NL SE

17P Request for examination filed

Effective date: 19820422

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 5068

Country of ref document: AT

Date of ref document: 19831115

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3161219

Country of ref document: DE

Date of ref document: 19831124

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19850328

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19890308

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19890309

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19890313

Year of fee payment: 9

ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19890331

Year of fee payment: 9

Ref country code: GB

Payment date: 19890331

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19890412

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19890428

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19891201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19900330

Ref country code: AT

Effective date: 19900330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19900331

Ref country code: LI

Effective date: 19900331

Ref country code: CH

Effective date: 19900331

Ref country code: BE

Effective date: 19900331

BERE Be: lapsed

Owner name: MERCK PATENT G.M.B.H.

Effective date: 19900331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19901001

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19901130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 81102377.9

Effective date: 19910109